NO20055238L - Kondenserte N-heterocykliske forbindelser og deres anvendelse som CRF-reseptorantagonister - Google Patents

Kondenserte N-heterocykliske forbindelser og deres anvendelse som CRF-reseptorantagonister

Info

Publication number: NO20055238L
Authority: NO; Norway
Prior art keywords: alkyl; halo; cyano; alkoxy; hydrogen
Prior art date: 2003-04-09

Application number

NO20055238A

Other languages

English (en)

Norwegian (no)

Other versions

NO20055238D0 (no

Inventor

Daniele Andreotti

Aldo Feriani

Romano Di Fabio

Gabriella Gentile

Giovanni Bernasconi

Emiliano Castiglinoni

Stefania Contini

Elettra Fazzolari

Mario Mattioli

Original Assignee

Neurocrine Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-09

Filing date

2005-11-08

Publication date

2006-01-09

2005-11-08 Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc

2005-11-08 Publication of NO20055238D0 publication Critical patent/NO20055238D0/no

2006-01-09 Publication of NO20055238L publication Critical patent/NO20055238L/no

Links

108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 14
125000004093 cyano group Chemical group *C#N 0.000 abstract 8
229910052739 hydrogen Inorganic materials 0.000 abstract 8
239000001257 hydrogen Substances 0.000 abstract 8
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 7
125000001475 halogen functional group Chemical group 0.000 abstract 7
125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 6
125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 6
125000003545 alkoxy group Chemical group 0.000 abstract 6
150000002431 hydrogen Chemical class 0.000 abstract 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 5
229910052736 halogen Inorganic materials 0.000 abstract 5
150000002367 halogens Chemical class 0.000 abstract 5
150000001875 compounds Chemical class 0.000 abstract 4
229910052757 nitrogen Chemical group 0.000 abstract 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
102000012289 Corticotropin-Releasing Hormone Human genes 0.000 abstract 2
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 abstract 2
239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
229910052799 carbon Inorganic materials 0.000 abstract 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
-1 nitro, hydroxy Chemical group 0.000 abstract 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
150000001721 carbon Chemical group 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
125000004001 thioalkyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Endocrinology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Otolaryngology (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)

NO20055238A 2003-04-09 2005-11-08 Kondenserte N-heterocykliske forbindelser og deres anvendelse som CRF-reseptorantagonister NO20055238L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0308208.8A GB0308208D0 (en)	2003-04-09	2003-04-09	Chemical compounds
US48532203P	2003-07-07	2003-07-07
PCT/IB2004/001350 WO2004094420A1 (en)	2003-04-09	2004-04-07	Condensed n-heterocyclic compounds and their use as crf receptor antagonists

Publications (2)

Publication Number	Publication Date
NO20055238D0 NO20055238D0 (no)	2005-11-08
NO20055238L true NO20055238L (no)	2006-01-09

Family

ID=33312357

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20055238A NO20055238L (no)	2003-04-09	2005-11-08	Kondenserte N-heterocykliske forbindelser og deres anvendelse som CRF-reseptorantagonister

Country Status (21)

Country	Link
US (2)	US7427630B2 (is)
EP (3)	EP2186813A1 (is)
JP (2)	JP4866722B2 (is)
KR (1)	KR20060021826A (is)
CN (1)	CN1805958A (is)
AR (1)	AR044005A1 (is)
AT (2)	ATE473226T1 (is)
AU (1)	AU2004232551C1 (is)
BR (1)	BRPI0409117A (is)
CA (1)	CA2521929C (is)
DE (2)	DE602004027998D1 (is)
GB (1)	GB0308208D0 (is)
IS (1)	IS8119A (is)
MA (1)	MA27796A1 (is)
MX (1)	MXPA05010874A (is)
NO (1)	NO20055238L (is)
NZ (1)	NZ542780A (is)
PL (1)	PL378755A1 (is)
RU (1)	RU2382785C2 (is)
TW (1)	TW200508232A (is)
WO (2)	WO2004094420A1 (is)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0117396D0 (en)	2001-07-17	2001-09-05	Glaxo Group Ltd	Chemical compounds
SI1668014T1 (sl)	2003-09-17	2009-06-30	Janssen Pharmaceutica Nv	Kondenzirane heterociklične spojine kot modulatorji serotoninskih receptorjev
CA2550948A1 (en) *	2003-12-22	2005-07-14	Sb Pharmco Puerto Rico Inc.	Crf receptor antagonists and methods relating thereto
WO2005103690A2 (en) *	2004-04-24	2005-11-03	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)
DE602005014375D1 (de) *	2004-10-19	2009-06-18	Neurocrine Biosciences Inc	Crf-rezeptor-antagonisten und zugehörige verfahren
GB0519957D0 (en) *	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
GB0507195D0 (en) *	2005-04-08	2005-05-18	Sb Pharmco Inc	Process for preparing bicyclic compounds
GB0507198D0 (en) *	2005-04-08	2005-05-18	Sb Pharmco Inc	Process for preparing bicyclic compounds
US7598255B2 (en)	2005-08-04	2009-10-06	Janssen Pharmaceutica Nv	Pyrimidine compounds as serotonin receptor modulators
US8088779B2 (en) *	2005-09-30	2012-01-03	Smithkline Beecham (Cork) Limited	Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
US8329701B2 (en)	2006-07-06	2012-12-11	Array Biopharma Inc.	Dihydrofuro pyrimidines as AKT protein kinase inhibitors
EP2049500B1 (en) *	2006-07-06	2011-09-07	Array Biopharma, Inc.	Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) *	2006-07-06	2011-11-22	Array Biopharma Inc.	Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ATE532789T1 (de)	2006-07-06	2011-11-15	Array Biopharma Inc	Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
US9409886B2 (en)	2007-07-05	2016-08-09	Array Biopharma Inc.	Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN101918373B (zh)	2007-07-05	2013-06-05	阵列生物制药公司	作为akt蛋白激酶抑制剂的嘧啶基环戊烷
CN103396409B (zh)	2007-07-05	2015-03-11	阵列生物制药公司	作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US8846683B2 (en)	2007-07-05	2014-09-30	Array Biopharma, Inc.	Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US20090118276A1 (en) *	2007-11-02	2009-05-07	Wyeth	Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
US8853216B2 (en) *	2008-01-09	2014-10-07	Array Biopharma, Inc.	Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
NZ586346A (en) *	2008-01-09	2012-02-24	Array Biopharma Inc	Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
TW200936591A (en) *	2008-01-22	2009-09-01	Takeda Pharmaceutical	Tricyclic compounds and use thereof
HRP20201352T1 (hr) *	2008-02-28	2020-11-27	Nippon Shinyaku Co., Ltd.	Inhibitor fibroze
AR071717A1 (es) *	2008-05-13	2010-07-07	Array Biopharma Inc	Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
KR102021157B1 (ko)	2011-04-01	2019-09-11	제넨테크, 인크.	Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
TR201815685T4 (tr)	2011-04-01	2018-11-21	Genentech Inc	Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
GB201113538D0 (en)	2011-08-04	2011-09-21	Karobio Ab	Novel estrogen receptor ligands
HK1207304A1 (en) *	2012-04-23	2016-01-29	Hmnc Value Gmbh	Crhr1 antagonists for use in the treatment of patients having crh overactivity
ES2704744T3 (es)	2012-06-13	2019-03-19	Incyte Holdings Corp	Compuestos tricíclicos sustituidos como inhibidores de FGFR
GB201210686D0 (en)	2012-06-15	2012-08-01	Holsboermaschmeyer Neurochemie Gmbh	V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
EA035095B1 (ru)	2013-04-19	2020-04-27	Инсайт Холдингс Корпорейшн	Бициклические гетероциклы в качестве ингибиторов fgfr
GB201310782D0 (en)	2013-06-17	2013-07-31	Max Planck Innovation Gmbh	Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MX373169B (es)	2015-02-20	2020-04-24	Incyte Holdings Corp	Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200590A (es)	2018-05-04	2021-04-26	Incyte Corp	Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr)	2018-05-04	2021-03-10	Incyte Corp	Sels d'un inhibiteur de fgfr
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
TWI891666B (zh)	2019-10-14	2025-08-01	美商英塞特公司	作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
EP4069696A1 (en)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt)	2019-12-04	2022-08-16	Incyte Corp	Derivados de um inibidor de fgfr
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
TW202304459A (zh)	2021-04-12	2023-02-01	美商英塞特公司	包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
EP4352059A1 (en)	2021-06-09	2024-04-17	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2023166067A1 (en)	2022-03-02	2023-09-07	Syngenta Crop Protection Ag	Microbiocidal pyridazinone amide derivatives
WO2024132895A1 (en)	2022-12-19	2024-06-27	Syngenta Crop Protection Ag	Microbiocidal dihydrooxadiazinyl pyridazinone compounds

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5169857A (en)	1988-01-20	1992-12-08	Bayer Aktiengesellschaft	7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
NO177005C (no)	1988-01-20	1995-07-05	Bayer Ag	Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
GB8810553D0 (en)	1988-05-05	1988-06-08	Smith D W	Integrated hydraulic pedal
GB2248618B (en)	1988-06-17	1993-01-06	Wyeth John & Brother Ltd	Process for preparing pyridine derivatives
JP2541702B2 (ja)	1989-10-11	1996-10-09	帝人株式会社	二環性ピリミジン誘導体、その製造方法およびそれを有効成分とする医薬製剤
DE4022414A1 (de)	1990-07-13	1992-01-16	Bayer Ag	Substituierte pyrrolo-pyridine
WO1992012718A1 (en)	1991-01-23	1992-08-06	Gensia, Inc.	Adenosine kinase inhibitors
GB9125842D0 (en)	1991-12-04	1992-02-05	Ici Plc	Heterocyclic derivatives
US5502187A (en)	1992-04-03	1996-03-26	The Upjohn Company	Pharmaceutically active bicyclic-heterocyclic amines
FI944602A0 (fi)	1992-04-03	1994-10-03	Upjohn Co	Farmaseuttisesti aktiiviset bisyklis-heterosykliset amiinit
JPH0710876A (ja)	1993-06-24	1995-01-13	Teijin Ltd	４位に環状アミノ基を有するピロロ［２，３―ｄ］ピリミジン
RU2153494C2 (ru)	1993-10-12	2000-07-27	Дзе Дюпон Мерк Фармасьютикал Компани	1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
PL313973A1 (en)	1993-10-12	1996-08-05	Du Pont Merck Pharma	1 n-alkyl-n-arylopyrimidin amines and their derivatives
TW530047B (en)	1994-06-08	2003-05-01	Pfizer	Corticotropin releasing factor antagonists
WO1995034563A1 (en)	1994-06-16	1995-12-21	Pfizer Inc.	Pyrazolo and pyrrolopyridines
EP0729758A3 (en)	1995-03-02	1997-10-29	Pfizer	Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
US6403599B1 (en)	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
US5955613A (en)	1995-10-13	1999-09-21	Neurogen Corporation	Certain pyrrolopyridine derivatives; novel CRF1 specific ligands
AU738304B2 (en)	1995-10-13	2001-09-13	Neurogen Corporation	Certain pyrrolopyridine derivatives; novel CRF 1 specific ligands
US6492520B1 (en)	1996-08-06	2002-12-10	Pfizer Inc	Substituted pyrido-or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
TW477787B (en)	1996-08-27	2002-03-01	Pfizer	Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
IL127566A0 (en)	1996-08-28	1999-10-28	Pfizer	Substituted 6,5-hetero- bicyclic derivatives
JP2001511813A (ja) *	1997-02-18	2001-08-14	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	Ｃｒｆレセプターアンタゴニストおよびそれらに関連する方法
ID24300A (id)	1997-08-05	2000-07-13	Pfizer Prod Inc	4-AMINOPIROL(3,2-d)PIRIMIDIN SEBAGAI ANTAGONIS-ANTAGONIS RESEPTOR NEUROPEPTIDA Y
JP2002510687A (ja) *	1998-04-02	2002-04-09	ニューロゲンコーポレイション	アミノアルキル置換ピロロ［２，３−ｂ］ピリジンおよびピロロ［２，３−ｄ］ピリミジン誘導体：ｃｒｆ１レセプタのモジュレータ
JPH11335376A (ja)	1998-05-25	1999-12-07	Taisho Pharmaceut Co Ltd	アリールテトラヒドロピリジン誘導体
JP2000086663A (ja)	1998-09-09	2000-03-28	Taisho Pharmaceut Co Ltd	アリールテトラヒドロピリジン誘導体
JP2002540206A (ja)	1999-03-11	2002-11-26	ニューロゲンコーポレイション	アリールの縮合した２，４−二置換ピリジン：ｎｋ３受容体リガンド
JP2002540203A (ja)	1999-03-29	2002-11-26	ニューロゲンコーポレイション	Ｎｋ−３および／またはｇａｂａ（ａ）受容体リガンドとしての４−置換キノリン誘導体
FR2791675B1 (fr)	1999-03-30	2001-05-04	Synthelabo	Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique
EP1040831A3 (en)	1999-04-02	2003-05-02	Pfizer Products Inc.	Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
WO2000066585A1 (en)	1999-04-30	2000-11-09	Neurogen Corporation	9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
IL148903A0 (en)	1999-09-30	2002-09-12	Neurogen Corp	Certain alkylene diamine-substituted heterocycles
US6525067B1 (en)	1999-11-23	2003-02-25	Pfizer Inc	Substituted heterocyclic derivatives
HRP20020599A2 (en)	2000-01-18	2004-08-31	Pfizer Prod Inc	Corticotropin releasing factor antagonists
AR028782A1 (es)	2000-07-05	2003-05-21	Taisho Pharmaceutical Co Ltd	Derivados heterociclicos tetrahidropiridino o piperidino
WO2002019975A1 (fr)	2000-09-05	2002-03-14	Taisho Pharmaceutical Co., Ltd.	Stimulants de la croissance des cheveux
GB0100622D0 (en)	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical compounds V111
US20040110785A1 (en)	2001-02-02	2004-06-10	Tao Wang	Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
ES2255610T3 (es)	2001-04-30	2006-07-01	Glaxo Group Limited	Antagonistas de los receptores de crf.
IL158062A0 (en)	2001-04-30	2004-03-28	Glaxo Group Ltd	Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
JP2004530702A (ja)	2001-05-21	2004-10-07	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	Ｃｒｆ受容体アンタゴニストとしてのトリ−およびテトラアザ−アセナフチレン誘導体
US7462622B2 (en)	2001-06-12	2008-12-09	Glaxo Group Limited	Pyrrolo[2, 3-d] pyrimidine derivatives as corticotropin releasing factor antagonists
GB0117396D0 (en)	2001-07-17	2001-09-05	Glaxo Group Ltd	Chemical compounds
US7273871B2 (en)	2001-07-17	2007-09-25	Sb Pharmco Puerto Rico Inc.	Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists
AU2002336462A1 (en)	2001-09-06	2003-03-24	Millennium Pharmaceuticals, Inc.	Piperazine and homopiperazine compounds
SE0201980D0 (sv)	2002-06-24	2002-06-24	Astrazeneca Ab	Novel compounds
DE602004005960T2 (de)	2003-01-16	2008-01-17	Sb Pharmco Puerto Rico Inc.	Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
EP1610782A1 (en) *	2003-03-27	2006-01-04	Boehringer Ingelheim International GmbH	Antiviral combination of a dipyridodiazepinone and a further antiretroviral compound
US20070021429A1 (en)	2003-04-09	2007-01-25	Yves St-Denis	Condensed n-heterocyclic compounds and their use as crf receptor antagonists
ATE388150T1 (de)	2003-12-22	2008-03-15	Sb Pharmco Inc	Crf-rezeptorantagonisten und diese betreffende verfahren
CA2550948A1 (en)	2003-12-22	2005-07-14	Sb Pharmco Puerto Rico Inc.	Crf receptor antagonists and methods relating thereto
US20070293511A1 (en)	2003-12-22	2007-12-20	Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation	Crf Receptor Antagonists and Methods

2003
- 2003-04-09 GB GBGB0308208.8A patent/GB0308208D0/en not_active Ceased
2004
- 2004-04-07 CN CNA2004800161898A patent/CN1805958A/zh active Pending
- 2004-04-07 EP EP08169936A patent/EP2186813A1/en not_active Withdrawn
- 2004-04-07 JP JP2006506558A patent/JP4866722B2/ja not_active Expired - Fee Related
- 2004-04-07 AT AT04726237T patent/ATE473226T1/de not_active IP Right Cessation
- 2004-04-07 AU AU2004232551A patent/AU2004232551C1/en not_active Ceased
- 2004-04-07 BR BRPI0409117-5A patent/BRPI0409117A/pt not_active IP Right Cessation
- 2004-04-07 MX MXPA05010874A patent/MXPA05010874A/es active IP Right Grant
- 2004-04-07 PL PL378755A patent/PL378755A1/pl not_active Application Discontinuation
- 2004-04-07 EP EP04726237A patent/EP1611133B1/en not_active Expired - Lifetime
- 2004-04-07 US US10/552,493 patent/US7427630B2/en not_active Expired - Lifetime
- 2004-04-07 CA CA2521929A patent/CA2521929C/en not_active Expired - Fee Related
- 2004-04-07 TW TW093109539A patent/TW200508232A/zh unknown
- 2004-04-07 DE DE602004027998T patent/DE602004027998D1/de not_active Expired - Lifetime
- 2004-04-07 AR ARP040101187A patent/AR044005A1/es unknown
- 2004-04-07 NZ NZ542780A patent/NZ542780A/en unknown
- 2004-04-07 WO PCT/IB2004/001350 patent/WO2004094420A1/en not_active Ceased
- 2004-04-07 RU RU2005134652/04A patent/RU2382785C2/ru not_active IP Right Cessation
- 2004-04-07 KR KR1020057019098A patent/KR20060021826A/ko not_active Ceased
- 2004-04-08 DE DE602004027900T patent/DE602004027900D1/de not_active Expired - Lifetime
- 2004-04-08 WO PCT/IB2004/001283 patent/WO2004094419A1/en not_active Ceased
- 2004-04-08 JP JP2006506536A patent/JP2006522798A/ja active Pending
- 2004-04-08 EP EP04726587A patent/EP1618107B1/en not_active Expired - Lifetime
- 2004-04-08 AT AT04726587T patent/ATE472547T1/de not_active IP Right Cessation
2005
- 2005-11-08 MA MA28585A patent/MA27796A1/fr unknown
- 2005-11-08 NO NO20055238A patent/NO20055238L/no not_active Application Discontinuation
- 2005-11-08 IS IS8119A patent/IS8119A/is unknown
2007
- 2007-10-31 US US11/931,313 patent/US20110172255A1/en not_active Abandoned

Also Published As

Publication number	Publication date
RU2382785C2 (ru)	2010-02-27
EP1618107B1 (en)	2010-06-30
RU2005134652A (ru)	2006-05-10
GB0308208D0 (en)	2003-05-14
MA27796A1 (fr)	2006-03-01
JP2006522799A (ja)	2006-10-05
AU2004232551B2 (en)	2008-09-11
US7427630B2 (en)	2008-09-23
CA2521929A1 (en)	2004-11-04
CN1805958A (zh)	2006-07-19
NO20055238D0 (no)	2005-11-08
EP1611133B1 (en)	2010-07-07
EP1611133A1 (en)	2006-01-04
PL378755A1 (pl)	2006-05-15
WO2004094419A1 (en)	2004-11-04
DE602004027900D1 (de)	2010-08-12
CA2521929C (en)	2011-12-06
US20110172255A1 (en)	2011-07-14
DE602004027998D1 (de)	2010-08-19
US20070004708A1 (en)	2007-01-04
KR20060021826A (ko)	2006-03-08
ATE472547T1 (de)	2010-07-15
JP4866722B2 (ja)	2012-02-01
ATE473226T1 (de)	2010-07-15
AU2004232551A1 (en)	2004-11-04
AR044005A1 (es)	2005-08-24
AU2004232551C1 (en)	2010-06-17
EP2186813A1 (en)	2010-05-19
JP2006522798A (ja)	2006-10-05
TW200508232A (en)	2005-03-01
EP1618107A1 (en)	2006-01-25
WO2004094420A1 (en)	2004-11-04
IS8119A (is)	2005-11-08
NZ542780A (en)	2009-02-28
BRPI0409117A (pt)	2006-03-28
MXPA05010874A (es)	2006-03-21

Legal Events

Date	Code	Title	Description
2011-11-28	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20055238L (no)	2006-01-09	Kondenserte N-heterocykliske forbindelser og deres anvendelse som CRF-reseptorantagonister
NO20083435L (no)	2008-10-10	Formuleringer
NO20081128L (no)	2008-06-18	4-fenyl-6-substituerte-pyrimidin-2-karbonitrilderivater
CY1111266T1 (el)	2015-08-05	Παραγωγα ετεροκυκλικου αμιδιου χρησιμα ως μικροβιοκτονα
AR076850A1 (es)	2011-07-13	Derivados sustituidos de indazol y aza-indazol como moduladores de la gamma secretasa.
AR035777A1 (es)	2004-07-14	Derivados de pirazol sustituidos, procesos para su preparacion, composiciones farmaceuticas que los contienen, y su uso en medicina
CA2540541A1 (en)	2005-04-14	Alkoxy substituted imidazoquinolines
RU2014121205A (ru)	2015-12-10	Производные азолов
NO20091012L (no)	2009-03-26	Kinazolinon- og isokinolinonacetamid derivater
WO2008115098A3 (fr)	2008-11-13	2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
DE60235729D1 (de)	2010-04-29	1,8-Naphthyridine als CRF Antagonisten
PE20070172A1 (es)	2007-05-15	DERIVADOS BICICLICOS COMO INHIBIDORES DE p38
MXPA05007494A (es)	2005-09-21	Nuevos compuestos.
CR20220116A (es)	2022-04-20	Compuestos heterocíclicos
NO984761L (no)	1998-12-14	Aminoisokinoliner og aminotienopyridinderivater og deres anvendelse som antiinflammatoriske midler
ATE359782T1 (de)	2007-05-15	Heteroaryl-substituierte pyrrol(2, 3- b)pyridin- derivate als crf-rezeptor-antagonisten
NO20053593L (no)	2005-10-21	Arylalkylkarbamat-derivater, fremgangsmate og anvendelse derav i terapi
AR071619A1 (es)	2010-06-30	Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen.
WO2009027626A3 (en)	2009-12-10	Improvements in or relating to organic compounds
MX2011009746A (es)	2011-09-29	Derivados de n-[(6-aza-biciclo[3.2.1]oct-5-il)-abril-metil]-hetero benzamida, su prepracion y su uso en terapeutica.
DE60226971D1 (de)	2008-07-17	Corticotropinfreisetzungsfaktor antagonisten
AR045209A1 (es)	2005-10-19	6-(1,1-difluoralquilo) -4- aminopicolinatos y su uso como herbicidas
AR078160A1 (es)	2011-10-19	Derivados de aminopiridina sustituidos, a su uso en terapia, y a composiciones farmaceuticas que los contiene
RU2007138380A (ru)	2009-04-27	1, 3-дигидробензимидазол-2-илиденовые амины в качестве ингибиторов репликации респираторного синцитиального вируса
AR033296A1 (es)	2003-12-10	Compuestos triciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica